Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Antipsychotic Agents

Antipsychotic Agents

Antipsychotic Agents are a class of medications primarily used to treat psychotic disorders, such as schizophrenia and bipolar disorder.
These agents work by modulating neurotransmitter systems in the brain, particularly dopamine and serotonin, to alleviate symptoms like hallucinations, delusions, and disorganized thinking.
Antipsychotic Agents can be classified into two main categories: typical (or first-generation) and atypical (or second-generation) antipsychotics, each with their own unique mechanisms of action and side effect profiles.
Researchers utilyze a variety of protocols and study designs to evaluate the efficacy, safety, and optimal use of these important pharmacotherapies for mental health conditions.

Most cited protocols related to «Antipsychotic Agents»

1
Antipsychotic Dose Equivalency Calculations
Cited 254 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Antipsychotic Agents Chlorpromazine Contraceptives, Oral Haloperidol Pharmaceutical Preparations Risperidone
2
Developing Consensus Criteria for Treatment-Resistant Schizophrenia
Cited 64 times
An iterative approach was adopted to develop criteria for treatment resistance in schizophrenia. Initially, a systematic review of definitions of treatment resistant schizophrenia used in clinical trials was conducted. A literature search of PubMed, PsycINFO, and Embase from January 1980 to January 2016 was undertaken using the search string: “(randomized or random or randomly) and (resistant or refractory or clozapine) and (schizophrenia)”. Titles and abstracts were reviewed to initially determine eligibility. The reference lists of each relevant paper were also searched, as were reference lists of relevant review papers, to further identify potential studies. Studies were included if they were randomized controlled trials of a pharmacological intervention in adults with treatment resistant schizophrenia. Studies were excluded if they were naturalistic, or purely of biomarkers such as neuroimaging measures, studies of adjuvant treatments or non-pharmacological interventions, studies of childhood onset or late onset schizophrenia.
The data extracted were: the prerequisites for previous antipsychotic treatment (requirements of different antipsychotics, minimum treatment duration, dose); the specified severity of symptoms; and whether there was a stipulation for resistance to be prospectively demonstrated. Additionally, whether criteria were operationalized or not was recorded. To be considered as operationalized, the study had to report criteria that met the following characteristics: 1) The use of a validated rating scale to determine symptom severity; 2) A specification of minimum symptom duration; and 3) A definition of adequate treatment that specified minimum dose, duration, and number of previous antipsychotics.
Subsequently, a working group - consisting of expert researchers and clinicians, scientists from the pharmaceutical industry and other specialists with experience and expertise in the area of schizophrenia - was identified by the co-chairs of the Treatment Response and Resistance in Psychosis working group (OH, JMK, CUC). This was augmented by attendees at TRRIP meetings held at international conferences in the field. Members of the final working group included researchers who had published recently in the field and researchers who attended the inaugural TRRIP meeting at the Schizophrenia International Research Society Biennial meeting in 2014. The working group mapped out the key criteria and operationalized them.
Second, members of the TRRIP working group were contacted and invited to take part in an on-line survey to identify key areas of agreement and disagreement. The survey was developed by the TRRIP co-chairs and modified with input from TRRIP work group members. In its final version (see Appendix 1), the survey was conducted using SurveyMonkey (www.surveymonkey.com). 48 researchers and clinicians were invited by email to take part in the survey. Over the 30-day collection period, 29 responses (60%), covering 13 countries, were received to the on-line survey; 3 (10%) responses were incomplete. See supplementary information for a summary of the responses to individual items. These responses were synthesized and refined during subsequent discussions amongst the whole group to derive the consensus recommendations for both minimum and optimum criteria.
Third, the working group met to consider and revise criteria for which there was a lack of consensus. The revised criteria were circulated to the TRRIP working group members, and presented as part of an open workshop at an international meeting in the field for further discussion, input and refinement. Finally, consensus was reached regarding this publication through review by all authors.
Howes O.D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N.J., Birnbaum M.L., Bloomfield M.A., Bressan R.A., Buchanan R.W., Carpenter W.T., Castle D.J., Citrome L., Daskalakis Z.J., Davidson M., Drake R.J., Dursun S., Ebdrup B.H., Elkis H., Falkai P., Fleischacker W.W., Gadelha A., Gaughran F., Glenthøj B.Y., Graff-Guerrero A., Hallak J.E., Honer W.G., Kennedy J., Kinon B.J., Lawrie S.M., Lee J., Leweke F.M., MacCabe J.H., McNabb C.B., Meltzer H., Möller H.J., Nakajima S., Pantelis C., Reis Marques T., Remington G., Rossell S.L., Russell B.R., Siu C.O., Suzuki T., Sommer I.E., Taylor D., Thomas N., Üçok A., Umbricht D., Walters J.T., Kane J, & Correll C.U. (2016). Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. The American journal of psychiatry, 174(3), 216-229.
Publication 2016
Adult Antipsychotic Agents ARID1A protein, human Biological Markers Clozapine Conferences Eligibility Determination Pharmaceutical Adjuvants Psychotic Disorders Schizophrenia Schizophrenia, Treatment-Resistant Specialists
3
Early Parkinson's Disease Cohort Study
Cited 48 times
PD and HC subjects of similar age and gender from 24 study sites in the US (18), Europe (5) and Australia (1) were enrolled after obtaining informed consent. We acknowledge that the early PD cohort likely includes a small number of subjects with other DAT deficit parkinsonian syndromes such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and cortical basal syndrome (CBS), which may be indistinguishable from PD at the earliest stages of disease. At each study visit, the investigators reassess the subject diagnosis to identify any non‐PD subjects.
This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines after approval of the local ethics committees of the participating sites. At enrollment, PD subjects were required to be age 30 years or older, untreated with PD medications (levodopa, dopamine agonists, MAO‐B inhibitors, or amantadine), within 2 years of diagnosis, Hoehn and Yahr <3, and to have either at least two of resting tremor, bradykinesia, or rigidity (must have either resting tremor or bradykinesia) or a single asymmetric resting tremor or asymmetric bradykinesia. All PD subjects underwent dopamine transporter (DAT) imaging with 123I Ioflupane or vesicular monoamine transporter (VMAT‐2) imaging with 18F AV133 (Australia only) and were only eligible if DAT or VMAT‐2 imaging demonstrated dopaminergic deficit consistent with PD in addition to clinical features of the disease. Study investigators evaluated enrolled PD subjects to assess absence of current or imminent (6 months) disability requiring PD medications, though subjects could initiate PD medications at any time after enrollment if the subject or investigator deemed it clinically necessary. Those subjects screened as potential PD subjects who were ineligible due to DAT or VMAT‐2 scans without evidence of dopaminergic deficit (SWEDD) were eligible to be enrolled in a SWEDD cohort.4 HC subjects were required to be age 30 years or older without an active, clinically significant neurological disorder or a first‐degree relative with PD. All enrolled subjects agreed to complete all study evaluations, including lumbar puncture.
PD and SWEDD subjects were excluded if they had a clinical diagnosis of dementia or had taken PD medications within 60 days of baseline or for longer than 60 days in total. HC subjects were excluded if they had a Montreal Cognitive Assessment (MoCA) total score ≤26. All subjects were excluded if they were treated with neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative within 6 months or were currently treated with anticoagulants that might preclude safe completion of the lumbar puncture.
Marek K., Chowdhury S., Siderowf A., Lasch S., Coffey C.S., Caspell‐Garcia C., Simuni T., Jennings D., Tanner C.M., Trojanowski J.Q., Shaw L.M., Seibyl J., Schuff N., Singleton A., Kieburtz K., Toga A.W., Mollenhauer B., Galasko D., Chahine L.M., Weintraub D., Foroud T., Tosun‐Turgut D., Poston K., Arnedo V., Frasier M, & Sherer T. (2018). The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 5(12), 1460-1477.
Publication 2018
123I-ioflupane Amantadine Amphetamine Anticoagulants Antipsychotic Agents Bradykinesia Cortex, Cerebral Dementia Diagnosis Disabled Persons Dopamine Agonists Gender Hydrochloride, Dopamine Levodopa Methyldopa Methylphenidate Metoclopramide Monoamine Oxidase Inhibitors Multiple System Atrophy Muscle Rigidity Nervous System Disorder Parkinsonian Disorders Pharmaceutical Preparations Progressive Supranuclear Palsy Punctures, Lumbar Radionuclide Imaging Regional Ethics Committees Reserpine Resting Tremor SLC6A3 protein, human Syndrome Vesicular Monoamine Transport Proteins Volumetric-Modulated Arc Therapy
4
Alzheimer's Disease Risk Factors Study
Cited 47 times
A total of 22 subjects were recruited in this study including 8 young controls (4 men and 4 women, age range: 24–40 years, mean 31) and 14 older adults (6 men and 8 women, age range: 50–73 years, mean 61). In order to match the prevalence of AD in the older population, 1 AD and 2 MCI patients were included as positive controls whose diagnoses were based on consensus conference case reviews. The rest of the older individuals were selected from a carefully characterized cohort known as The Wisconsin Registry for AD Prevention (WRAP), many of whom have a parent with AD and are considered at high risk to develop AD (20 (link)). The study was approved by the Institutional Review Board at the University of Wisconsin. All participants provided informed consent prior to participation. The consent process included an initial screening for MRI and PET compatibility and discussion of major safety exclusion criteria. Study exclusion criteria included contraindications to MRI and PET; less than 10 years of education; pregnancy; major head trauma, psychiatric disease such as schizophrenia and substance dependence, or abnormal structural MRI and neuropsychological testing as part of study participation. Excluded medications include psychoactive medications, neuroleptics, short or long acting nitrates, and warfarin or other drugs that may affect CBF (such as caffeine within 3 hours and nicotine within 1 hour of the imaging exam).
Xu G., Rowley H.A., Wu G., Alsop D.C., Shankaranarayanan A., Dowling M., Christian B.T., Oakes T.R, & Johnson S.C. (2010). Reliability and Precision of Pseudo-continuous Arterial Spin Labeling Perfusion MRI on 3.0 T and Comparison with 15O-water PET in Elderly Subjects at Risk for Alzheimer’s Disease. NMR in biomedicine, 23(3), 286-293.
Publication 2010
Aged Antipsychotic Agents Caffeine Conferences Craniocerebral Trauma Diagnosis Ethics Committees, Research Mental Disorders Nicotine Nitrates Parent Patients Pharmaceutical Preparations Pregnancy Psychotropic Drugs Safety Schizophrenia Substance Dependence Warfarin Woman
5
Intention-to-Treat Analysis of Antipsychotic Switching
Cited 38 times
The intention-to-treat (ITT) population, consisting of all patients who took at least one dose of the study medication and had at least one evaluation for the primary efficacy endpoint after the cross titration period, was used for the efficacy and safety assessment. Subgroup analyses based on the reasons for switching and the previous antipsychotic treatment were also performed. A last observation carried forward (LOCF) approach was applied to handle the missing values for the efficacy analysis. To compare the baseline characteristics between the two subgroups with different reasons for enrolling, the chi-square test or Fisher’s exact test were used for categorical variables and Student’s t test for continuous variables. For the primary and the other efficacy endpoints, a two-way ANOVA with one-way repeated was used to analyze the mean change in PANSS and CGI-S scores between groups. A p value of less than 0.05 was considered to be statistically significant. All statistical analyses were performed with SPSS software version 17 (SPSS Inc., Chicago, IL, USA).
Pan P.Y., Lee M.S, & Yeh C.B. (2015). The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population. BMC Psychiatry, 15, 1.
Full text: Click here
Publication 2015
Antipsychotic Agents neuro-oncological ventral antigen 2, human Patients Safety Student Titrimetry

Most recents protocols related to «Antipsychotic Agents»

1
Prescription Drug Use in Hemophilia

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Age Groups Analgesics Anti-Anxiety Agents Anti-Inflammatory Agents, Non-Steroidal Antidepressive Agents Antiepileptic Agents Antipsychotic Agents Anxiety Drug Abuser inhibitors Joints Opioids Pain Pharmaceutical Preparations Prescription Drugs Steroids
2
Hemophilia Treatment Patterns and Complications

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Anti-Inflammatory Agents, Non-Steroidal Antidepressive Agents Antiepileptic Agents Antipsychotic Agents Anxiety Arthropathy Childbirth Diagnosis Hemophilia A inhibitors Joints Operative Surgical Procedures Opioids Pain Patients Pharmaceutical Preparations Prescription Drugs Steroids
3
First-Episode Major Depressive Disorder Patients
Participants were recruited at the psychiatric outpatient department of the First Hospital of Shanxi Medical University from 2015 to 2017. Inclusion criteria were as follows: (1) fulfilling DSM-IV criteria for MDD, diagnosed by two trained psychiatrists using the Structured Clinical Interview for DSM-IV Disorders (SCID); (2) 17-item Hamilton Depression Scale (HAMD) score of more than 23; (3) age 18-60 years old, Han nationality; (4) no prior medication, including antidepressant, antipsychotic drugs, thyroid hormone therapy, hypoglycemic agents, antihypertensive and lipid-lowering drugs; and (5) depression symptoms were first-episode and the disease duration of no more than 24 months. Exclusion criteria included: (1) pregnant or breastfeeding women; (2) concurrent DSM-IV axis I disorder including bipolar disorder, schizophrenia, and schizoaffective or severe medical conditions; (3) substance use disorder except for tobacco; and (4) unwillingness to provide informed consent.
All participants provided written informed consent. This study was approved by the Institutional Review Board (IRB) of the First Hospital of Shanxi Medical University (No. 2016-Y27).
Peng P., Wang Q., Lang X., Liu T, & Zhang X.Y. (2023). Clinical symptoms, thyroid dysfunction, and metabolic disturbances in first-episode drug-naïve major depressive disorder patients with suicide attempts: A network perspective. Frontiers in Endocrinology, 14, 1136806.
Full text: Click here
Publication 2023
Antidepressive Agents Antihypertensive Agents Antipsychotic Agents Bipolar Disorder Depressive Symptoms Epistropheus Ethics Committees, Research Hypoglycemic Agents Hypolipidemic Agents Outpatients Pharmaceutical Preparations Psychiatrist Schizophrenia Therapeutics Thyroid Hormones Tobacco Use Disorder Woman
4
Observational Study of Antipsychotic Medication Use
RE-KINECT was a prospective, real-world, observational, multicenter study conducted at 37 outpatient psychiatry clinics (e.g., research institutions, community health centers, private practices) in the United States from April 2017 to January 2018 [17 (link)]. In brief, this study included adults with ≥ 3 months of lifetime exposure to antipsychotic medication and ≥ 1 clinician-confirmed psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria [19 ]. The 3 month lifetime antipsychotic exposure requirement was based on the Schooler-Kane criteria for TD research and DSM-IV-TR [20 (link), 21 ], and it is consistent with current American Psychiatric Association guidelines (DSM-5-TR) [22 ]. All patients provided written informed consent prior to participation; Institutional Review Board approval was obtained at each site.
Tanner C.M., Caroff S.N., Cutler A.J., Lenderking W.R., Shalhoub H., Pagé V., Franey E.G., Serbin M, & Yonan C. (2023). Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study. Journal of Patient-Reported Outcomes, 7, 21.
Full text: Click here
Publication 2023
Adult Antipsychotic Agents Ethics Committees, Research Patients
5
Alzheimer's and Mild Cognitive Impairment Diagnostic Protocol
Patients with probable AD and ADMCI were recruited consecutively from April 2015 to March 2022 at the outpatient clinic in the Department of Psychiatry in Nippon Life Hospital. All patients met the diagnosis criteria of probable AD and ADMCI according to the National Institute on Aging-Alzheimer’s Association (NIA-AA)61 (link),62 (link) and the DSM-V63 . Inclusion criteria for AD and ADMCI patients were as follows: (1) no comorbidity of other types of dementia, neurological, or psychiatric disorders; (2) not taking antidementia, antipsychotic, or antianxiety drugs; and (3) no lacunar cerebral infarct lesions or ischemic changes greater than would be expected for the patient’s age on head MRI. 91 drug-free probable AD patients and 11 drug-free ADMCI patients met the inclusion criteria. One AD patient was excluded due to the lack of 120-s resting awake artifact-free EEG segments. Finally, 90 drug-free probable AD patients and 11 drug-free ADMCI patients were included in this study. During follow-up of the 11 ADMCI patients, six patients developed AD, one patient maintained cognitive function within normal limits in MMSE and ADAS-J cog, two patients have not yet had follow-up examinations one year after diagnosis, and two patients discontinued outpatient care. The 147 healthy subjects used in the present study were obtained from our previous study64 (link). The healthy subjects (without history of any neurological or psychiatric disorders) underwent clinical tests to ensure that their memory and other cognitive functions were within normal limits (MMSE: 29.7 ± 0.6; global Clinical Dementia Rating: 0). The mean age of healthy subjects (58 women and 89 men) was 49.7 ± 19.6 years (Table 1).
This study was approved by the ethics committee of Nippon Life Hospital and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all capable patients or their families.
Aoki Y., Takahashi R., Suzuki Y., Pascual-Marqui R.D., Kito Y., Hikida S., Maruyama K., Hata M., Ishii R., Iwase M., Mori E, & Ikeda M. (2023). EEG resting-state networks in Alzheimer’s disease associated with clinical symptoms. Scientific Reports, 13, 3964.
Full text: Click here
Publication 2023
Anti-Anxiety Agents Antipsychotic Agents Care, Ambulatory Cognition Dementia Diagnosis Ethics Committees, Clinical Head Healthy Volunteers Memory Mental Disorders Mini Mental State Examination Patients Pharmaceutical Preparations Physical Examination Stroke, Lacunar Woman

Top products related to «Antipsychotic Agents»

1
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
2
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
3
Haloperidol by Merck Group
Sourced in United States, United Kingdom, Sao Tome and Principe, Germany, France, Japan, Spain
Haloperidol is a laboratory reagent used in various research and analytical applications. It is a butyrophenone-class antipsychotic drug that acts as a dopamine D2 receptor antagonist. Haloperidol is commonly used as a reference standard and in the development and validation of analytical methods.
4
Spss version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
5
Clozapine by Merck Group
Sourced in United States, United Kingdom, Germany, Sao Tome and Principe, Israel, Macao
Clozapine is a laboratory instrument used for the detection and quantification of the antipsychotic drug clozapine. It is designed to provide accurate and reliable measurements of clozapine concentrations in biological samples, such as blood or plasma.
6
Spss statistics for window by IBM
Sourced in United States, United Kingdom, Belgium, Japan, Austria, Germany, Denmark
SPSS Statistics for Windows is an analytical software package designed for data management, analysis, and reporting. It provides a comprehensive suite of tools for statistical analysis, including regression, correlation, and hypothesis testing. The software is intended to assist users in gaining insights from their data through advanced analytical techniques.
7
Risperidone by Merck Group
Sourced in United States, United Kingdom, France, Germany
Risperidone is a medication used to treat various psychiatric conditions, including schizophrenia, bipolar disorder, and certain symptoms of autism. It is an antipsychotic drug that works by affecting the balance of certain natural substances in the brain.
8
Stata 14 by StataCorp
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
9
Spss version 19 by IBM
Sourced in United States, Japan, United Kingdom, Germany, India, China, Austria, Australia
SPSS version 19.0 is a statistical software package developed by IBM. It provides tools for data analysis, data management, and data visualization. The core function of SPSS is to enable users to conduct a wide range of statistical analyses, including regression, correlation, and non-parametric tests.

More about "Antipsychotic Agents"

Antipsychotic Agents, also known as neuroleptics or major tranquilizers, are a class of medications primarily used to manage psychotic disorders such as schizophrenia and bipolar disorder.
These pharmacotherapies work by modulating key neurotransmitter systems in the brain, particularly dopamine and serotonin, to alleviate symptoms like hallucinations, delusions, and disorganized thinking.
Antipsychotic Agents can be broadly classified into two main categories: typical (or first-generation) and atypical (or second-generation) antipsychotics.
Each category has unique mechanisms of action and side effect profiles, offering healthcare providers and researchers diverse options to optimize treatment plans for patients.
In the development and evaluation of Antipsychotic Agents, researchers utilize a variety of protocols and study designs, including randomized controlled trials (RCTs), observational studies, and pharmacokinetic/pharmacodynamic analyses.
These studies assess the efficacy, safety, and optimal use of these important medications for mental health conditions.
Commonly used Antipsychotic Agents include Haloperidol, Clozapine, Risperidone, and others.
Statistical software such as SAS 9.4, SPSS version 20, and Stata 14 are often employed to analyze data and generate insights from these research efforts.
PubCompare.ai is a powerful tool that can help streamline the research process for Antipsychotic Agents.
By utilizing AI-driven insights, PubCompare.ai can assist researchers in locating the best protocols and products from literature, pre-prints, and patents, enabling data-driven decisions and optimized research protocols.